Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ?50%: KEYNOTE-598

Boyer, M.Sendur, M. A. N.Rodriguez-Abreu, D.Park, K.Lee, D. H.Cicin, I.Yumuk, P. F.2024-06-122024-06-1220211556-08641556-1380https://doi.org/10.1016/j.jtho.2021.01.322https://hdl.handle.net/20.500.14551/23126[Abstract Not Available]en10.1016/j.jtho.2021.01.322info:eu-repo/semantics/openAccessPhase III TrialRelapsed Malignant MesotheliomaImmune-Checkpoint-InhibitorPembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ?50%: KEYNOTE-598Conference Object163S61S62Q1WOS:000631349600006